|
1987 |
Listed on New York Stock Exchange |
|
720 |
Employees |
|
$206 mil. |
Market cap at December 31, 2000 |
|
$591 mil. |
Market cap at March 31, 2007 |
|
$770 mil. |
2007 revenue |
|
$51 mil. |
2007 income from continuing operations |
|
80 |
Currently marketed product families |
| 5 |
New product launches in 2007* |
| 9 |
ANDAs filed in 2007, including six internally developed |
| 45 |
ANDAs pending approval* |
|
20+ |
Strategic partners, including GSK, AstraZeneca, Elan, Solvay, BMS, IntelliPharmaceutics, Immtech, BioAlliance and Hana Biosciences |
* Including partner companies.
NYSE: PRX 
